News Conference News ACC 2024 Another Win for TAVI in Patients at Low-to-Intermediate Risk: DEDICATE-DZHK6 Yael L. Maxwell April 08, 2024
Presentation ACC 2022 5-Year Incidence, Outcomes and Predictors of Structural Valve Deterioration of Transcatheter and Surgical Aortic Bioprostheses: Insights from the CoreValve US Pivotal and SURTAVI Trials Presenter: Michael J. Reardon April 04, 2022
News Conference News ACC 2022 Self-Expanding TAVI Looks More Durable Than SAVR at 5 Years Michael O'Riordan April 04, 2022
News Conference News ACC 2017 SURTAVI Lends More Support to Use of TAVR in Intermediate-Risk Patients Todd Neale March 17, 2017
News Conference News ACC 2017 ACC 2017: CVD Outcomes for Evolocumab, Intermediate-Risk TAVR, Coronary Physiology Tests, and More Shelley Wood March 10, 2017
News Conference News ACC 2015 Follow-up TAVR Studies Reassure About Valve Durability, Outcomes Todd Neale March 15, 2015
Video » Interview ACC 2022: Insights from the CoreValve US Pivotal and SURTAVI Trials: Five-Year Incidence, Timing And Predictors of Hemodynamic Valve Deterioration ff Transcatheter snd Surgical Aortic Bioprostheses April 3, 2022